Biotech · Private company · Research Triangle Park, NC, US

G1 Therapeutics, Inc.

SEC CIK 0001560241

Track this companyFree. Adds G1 Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials152 recruiting or active

Pipeline programs30From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline30

CarboplatinPhase 3 · TNBC - Triple-Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 3 · TNBC - Triple-Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 3 · TNBC - Triple-Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 3 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
AtezolizumabPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
AvelumabPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
CarboplatinPhase 2 · Triple-Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
CarboplatinPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
CarboplatinPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Carboplatin (Investigator discretion)Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
CisplatinPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
CylophosphamidePhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
DocetaxelPhase 2 · Metastatic Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
DoxorubicinPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
EtoposidePhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
G1T38Phase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Triple-Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
OsimertinibPhase 2 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Pembrolizumab (Investigator discretion)Phase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Sacituzumab Govitecan-hziyPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TopotecanPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 2 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 2 · Metastatic Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 2 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TrilaciclibPhase 2 · Triple-Negative Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
G1T48Phase 1 · Carcinoma, Ductal, BreastClinicalTrials.gov · fetched Nov 12, 2026
PalbociclibPhase 1 · Carcinoma, Ductal, BreastClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials15

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 10, 2024ClinicalTrials.gov NCT06027268 · fetched Nov 12, 2026
Study of Trilaciclib and LurbinectidinPHASE2 · RECRUITING · started Oct 12, 2022ClinicalTrials.gov NCT05578326 · fetched Nov 12, 2026
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerPHASE2 · COMPLETED · started Mar 3, 2022ClinicalTrials.gov NCT05112536 · fetched Nov 12, 2026
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerPHASE2 · TERMINATED · started Dec 8, 2021ClinicalTrials.gov NCT05113966 · fetched Nov 12, 2026
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabPHASE2 · TERMINATED · started Jun 4, 2021ClinicalTrials.gov NCT04887831 · fetched Nov 12, 2026
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)PHASE3 · COMPLETED · started May 14, 2021ClinicalTrials.gov NCT04799249 · fetched Nov 12, 2026
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)PHASE2 · TERMINATED · started Apr 30, 2021ClinicalTrials.gov NCT04863248 · fetched Nov 12, 2026
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):PHASE3 · TERMINATED · started Jan 6, 2021ClinicalTrials.gov NCT04607668 · fetched Nov 12, 2026
Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World SettingUNKNOWN · started Aug 15, 2020ClinicalTrials.gov NCT05826756 · fetched Nov 12, 2026
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerPHASE1 · COMPLETED · started May 9, 2018ClinicalTrials.gov NCT03455270 · fetched Nov 12, 2026
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Mar 29, 2018ClinicalTrials.gov NCT03455829 · fetched Nov 12, 2026
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCPHASE2 · COMPLETED · started Jun 29, 2017ClinicalTrials.gov NCT03041311 · fetched Nov 12, 2026
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)PHASE2 · TERMINATED · started Feb 2, 2017ClinicalTrials.gov NCT02978716 · fetched Nov 12, 2026
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyPHASE1_PHASE2 · COMPLETED · started Oct 5, 2015ClinicalTrials.gov NCT02514447 · fetched Nov 12, 2026
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)PHASE1_PHASE2 · COMPLETED · started Jun 26, 2015ClinicalTrials.gov NCT02499770 · fetched Nov 12, 2026